See more : Ningbo Menovo Pharmaceutical Co., Ltd. (603538.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Response Genetics, Inc (RGDXQ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Response Genetics, Inc, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Three Sixty Solar Ltd. (VSOLF) Income Statement Analysis – Financial Results
- Berkeley Energia Limited (BKLRF) Income Statement Analysis – Financial Results
- USHG Acquisition Corp. (HUGS) Income Statement Analysis – Financial Results
- Samsung Electro-Mechanics Co., Ltd. (009150.KS) Income Statement Analysis – Financial Results
- Tidewater Renewables Ltd. (TDWRF) Income Statement Analysis – Financial Results
Response Genetics, Inc (RGDXQ)
Industry: Medical - Diagnostics & Research
Sector: Healthcare
Website: https://www.responsegenetics.com
About Response Genetics, Inc
Response Genetics, Inc., a life sciences company, researches, develops, markets, and sells pharmacogenomic tests for use in the treatment of cancer in the United States, Europe, and internationally. The company offers tests for measuring predictive factors for therapy response in tumor tissue samples. It provides testing services for non-small cell lung cancer, colorectal cancer, gastric and gastroesophageal cancer, melanoma and thyroid cancer, breast cancer, and glioma through its ResponseDX: Lung, ResponseDX: Colon, ResponseDX: Gastric, ResponseDX: Melanoma, ResponseDX: Thyroid, ResponseDX: Breast, ResponseDX: Glioma, and ResponseDX: Tissue of Origin test suites. The company also develops tests for other tumor types; and provides technical component and professional component testing services. It serves community based oncologists, pathologists, physician offices, hospitals, and pharmaceutical companies through its sales force. The company was formerly known as Bio Type, Inc. and changed its name to Response Genetics, Inc. in August 2000. Response Genetics, Inc. was founded in 1999 and is headquartered in Los Angeles, California.
| Metric | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 18.04M | 16.72M | 19.80M | 18.74M | 22.64M | 21.28M | 9.07M | 7.12M | 7.79M | 6.02M | 6.96M |
| Cost of Revenue | 14.10M | 10.01M | 10.46M | 10.42M | 11.73M | 10.46M | 5.72M | 3.59M | 4.05M | 2.46M | 1.79M |
| Gross Profit | 3.94M | 6.71M | 9.35M | 8.32M | 10.91M | 10.82M | 3.35M | 3.53M | 3.74M | 3.56M | 5.17M |
| Gross Profit Ratio | 21.85% | 40.12% | 47.20% | 44.41% | 48.18% | 50.84% | 36.90% | 49.55% | 48.06% | 59.18% | 74.30% |
| Research & Development | 5.48M | 1.73M | 1.61M | 2.13M | 1.32M | 1.61M | 2.29M | 2.16M | 2.46M | 1.26M | 1.02M |
| General & Administrative | 14.57M | 12.88M | 10.26M | 8.78M | 9.71M | 8.10M | 6.84M | 7.86M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 5.27M | 5.11M | 5.42M | 5.07M | 5.56M | 5.99M | 3.62M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 19.84M | 17.99M | 15.68M | 13.85M | 15.27M | 14.09M | 10.46M | 7.86M | 6.79M | 3.93M | 2.23M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 25.32M | 19.72M | 17.29M | 15.98M | 16.59M | 15.70M | 12.75M | 12.50M | 9.24M | 5.20M | 3.25M |
| Cost & Expenses | 39.42M | 29.73M | 27.75M | 26.39M | 28.32M | 26.16M | 18.47M | 16.09M | 13.29M | 7.65M | 5.03M |
| Interest Income | 49.00K | 74.00K | 48.00 | 27.00 | 149.00 | 682.00 | 22.27K | 374.66K | 517.65K | 138.60K | 71.07K |
| Interest Expense | 344.00K | 664.73K | 91.84K | 85.84K | 20.72K | 10.58K | 10.82K | 3.88K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.71M | 827.61K | 48.00 | 27.00 | 366.84K | 465.69K | 385.43K | 784.72K | 572.10K | 315.02K | 246.80K |
| EBITDA | -19.67M | -13.01M | -7.95M | -7.20M | -5.32M | -4.19M | -8.95M | -8.71M | -4.93M | -1.32M | 2.17M |
| EBITDA Ratio | -109.01% | -77.80% | -40.13% | -40.87% | -23.47% | -20.75% | -99.26% | -109.57% | -63.23% | -25.20% | 31.19% |
| Operating Income | -21.38M | -13.01M | -7.95M | -7.66M | -5.68M | -4.88M | -9.41M | -9.86M | -5.50M | -1.63M | 1.92M |
| Operating Income Ratio | -118.50% | -77.80% | -40.13% | -40.87% | -25.09% | -22.94% | -103.75% | -138.39% | -70.58% | -27.17% | 27.65% |
| Total Other Income/Expenses | 9.00K | -691.77K | 441.49K | -99.81K | -20.57K | 211.91K | 61.16K | 361.87K | 488.98K | 277.84K | 15.85K |
| Income Before Tax | -21.37M | -13.70M | -8.02M | -7.76M | -5.70M | -4.67M | -9.35M | -9.50M | -5.01M | -1.36M | 1.94M |
| Income Before Tax Ratio | -118.45% | -81.93% | -40.50% | -41.40% | -25.18% | -21.94% | -103.08% | -133.31% | -64.30% | -22.55% | 27.87% |
| Income Tax Expense | -1.18M | -162.88K | -541.13K | -384.22K | 20.72K | 1.26K | -4.79K | -12.75K | 44.02K | 800.00 | 1.05K |
| Net Income | -20.18M | -13.54M | -7.48M | -7.37M | -5.72M | -4.67M | -9.34M | -9.49M | -5.05M | -1.36M | 1.94M |
| Net Income Ratio | -111.88% | -80.96% | -37.77% | -39.35% | -25.28% | -21.95% | -103.03% | -133.13% | -64.87% | -22.56% | 27.86% |
| EPS | 0.00 | -0.35 | -0.22 | -0.28 | -0.30 | -0.26 | -0.70 | -0.93 | -0.72 | -0.50 | 0.37 |
| EPS Diluted | 0.00 | -0.35 | -0.22 | -0.28 | -0.30 | -0.26 | -0.70 | -0.93 | -0.72 | -0.50 | 0.31 |
| Weighted Avg Shares Out | 0.00 | 38.76M | 33.48M | 26.74M | 19.12M | 17.79M | 13.28M | 10.24M | 6.99M | 2.73M | 2.73M |
| Weighted Avg Shares Out (Dil) | 0.00 | 38.76M | 33.48M | 26.74M | 19.12M | 17.79M | 13.28M | 10.24M | 6.99M | 2.73M | 6.16M |
Source: https://incomestatements.info
Category: Stock Reports